Toshitsugu Fujita, Ph.D.
Dr. Toshitsugu Fujita is an Associate Professor / Research Professor of Hirosaki University Graduate School of Medicine and School of Medicine, and a Founder of Epigeneron. Prior to this position, he was an Assistant Professor at Osaka University and a postdoctoral fellow at University of Geneva Faculty of Medicine. During his professional career, Dr. Fujita has focused on molecular biology and epigenetics. He received a Ph.D. from Osaka University and M.S. and B.S. from Shizuoka University.
Ali Shilatifard, Ph.D.
Dr. Ali Shilatifard, Professor and Chairman of the Department of Biochemistry and Molecular Genetics and the Director, Simpson Querrey Institute for Epigenetics of the Northwestern University Feinberg School of Medicine, is a world renown biochemist and molecular biologist and a respected expert in the field of transcription and epigenetics. As a Jane Coffin Childs postdoctoral fellow, Shilatifard made a seminal contribution to the field of leukemia biology by identifying the first function of any of the MLL translocation partners. Since then, he has continued to contribute to the field of transcription, chromatin biology, and cancer biology through many discoveries including those of the COMPASS and SEC complexes, which are demonstrating to be central to the mechanisms involved in the development of leukemia. Currently, the inhibitors developed in Shilatifard’s laboratory towards the COMPASS family and the SEC are being tested for the treatment of childhood leukemia, brain cancer, and triple negative breast tumors. For his contributions to our understanding of cancer biology. Shilatifard has been recognized by the Leukemia and Lymphoma Society, as the recipient of the Sword of the American Cancer Society, and the AMGEN Award by the American Society of Biochemistry and Molecular Biology. Shilatifard was selected as an inaugural recipient of the Outstanding Investigator Award from the National Cancer Institute. He has served as a Senior Editor for the journal Science and is currently serving as the Editor for Science’s open access journal Science Advances.
Kentaro Yoshimatsu, Ph.D.
Dr. Kentaro Yoshimatsu has served as a scientific advisor to the company since February, 2021. He is the CEO at Rin Institute, a startup engaged in the development of antibody drugs in oncology. He was a R&D head and Executive Officer at Eisai. He has over 40 year experiences in leading research activities mainly in the oncology area at Eisai. He also served as the CEO at H3 Biomedicine in Boston. He received B.S., M.S. and Ph.D. degrees from the University of Tokyo.